ProShares Ultra Nasdaq BiotechnologyBIB
Type
ETF
Peer group
Alternative
Net assets
$91.7M
Expense ratio
0.95%
1-year return
+112.1%
3 years, a year
+31.8%
5 years, a year
+2.7%
12-month yield
0.19%
Holdings
278
What it aims to do.
ProShares Ultra Nasdaq Biotechnology (the Fund) seeks daily investment results, before fees and expenses, that correspond to two times (2x) the daily performance of the Nasdaq Biotechnology Index (the Index).
Top 10 holdings.
| Holding | % of fund |
|---|---|
| GILD Gilead Sciences, Inc. | 6.48% |
| N/A | 6.34% |
| VRTX Vertex Pharmaceuticals, Inc. | 6.27% |
| AMGN Amgen, Inc. | 6.15% |
| REGN Regeneron Pharmaceuticals, Inc. | 4.06% |
| N/A | 3.61% |
| N/A | 2.89% |
| N/A | 2.85% |
| N/A | 2.63% |
| ALNY Alnylam Pharmaceuticals, Inc. | 2.21% |
More on BIB.
- BIB overview
- BIB holdings
- BIB risk
- BIB costs
- BIB money in and out
- BIB share classes
- Compare BIB with other funds
Returns after fees, from the fund's SEC filings up to Aug 2026. Past returns are not a promise. Not financial advice.